Recent advancements of antiangiogenic combination therapies in ovarian cancer

Cancer Treat Rev. 2021 Jul:98:102224. doi: 10.1016/j.ctrv.2021.102224. Epub 2021 May 19.

Abstract

Ovarian cancer is a deadly malignancy with a growing therapeutic armamentarium, though achieving sustained benefit in the clinic remains largely elusive. Through biomarker and genetic analysis, several pathways of resistance and sensitivity to commonly used therapeutics have been identified, expanding the potential of identifying unique drug combinations and indicating new directions for improving clinical outcomes. Here, we review the mechanisms of angiogenic response and antiangiogenic therapy in ovarian cancer, as well as the interactions it exhibits with the immune and DNA damage response pathways. We discuss results from clinical trials examining the combinations of antiangiogenics, PARP inhibitors, and immune checkpoint inhibitors are also discussed, as well as several ongoing trials.

Keywords: Combination therapy; Immunotherapy; Ovarian cancer; PARP inhibitor; VEGF/VEGFR inhibitor.

Publication types

  • Review

MeSH terms

  • Angiogenesis Inhibitors / therapeutic use*
  • Animals
  • Antineoplastic Combined Chemotherapy Protocols
  • Female
  • Humans
  • Immune Checkpoint Inhibitors / therapeutic use*
  • Molecular Targeted Therapy*
  • Neovascularization, Pathologic / drug therapy*
  • Neovascularization, Pathologic / pathology
  • Ovarian Neoplasms / blood supply
  • Ovarian Neoplasms / drug therapy*
  • Ovarian Neoplasms / pathology
  • Poly(ADP-ribose) Polymerase Inhibitors / therapeutic use*

Substances

  • Angiogenesis Inhibitors
  • Immune Checkpoint Inhibitors
  • Poly(ADP-ribose) Polymerase Inhibitors